Read more

September 27, 2021
2 min watch
Save

VIDEO: Non-invasive PCC test offers high negative predictive value for prostate cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video Andres Correa, MD, discusses the MiR Sentinel PCC4 test, which has been shown to offer a high predictive value when testing for prostate cancer.

"The most important factor is the high negative predictive factor that they reported. This means that if the test is negative, you can feel very confident that the patient does not need a prostate biopsy," Correa, assistant professor in the department of surgery in the urologic oncology division at Fox Chase Cancer Center in Philadelphia.

In addition, the test is non-invasive and may not require the patient to undergo an MRI or visit a clinician’s office.

"With the pandemic this [test] is something that can potentially be done at home," Correa said.